{"corpus_id":9449984,"paper_sha":"702a10013255378ba8463bda8395026cc99cb89d","doi":"10.1200/JCO.2007.12.4487","arxiv_id":null,"pmid":18309951,"pmcid":"PMC4010133","mag_id":2167331614,"dblp_id":null,"acl_id":null,"title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.","year":2008,"publication_date":"2008-03-01","venue":"Journal of Clinical Oncology","journal":{"name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pages":"\n          1148-59\n        ","volume":"26 7"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","Review"],"pubmed_pub_types":["Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't","Research Support, U.S. Gov't, Non-P.H.S.","Practice Guideline"],"s2_fields_of_study":["Medicine"],"reference_count":40,"citation_count":2187,"influential_citation_count":95,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adenocarcinoma","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"},{"q":"pathology","mj":true,"ui":"Q000473"},{"q":"therapy","mj":false,"ui":"Q000628"}],"ui":"D000230"},{"d":"Clinical Trials as Topic","mj":false,"qs":[{"q":"standards","mj":true,"ui":"Q000592"}],"ui":"D002986"},{"d":"Disease Progression","mj":false,"ui":"D018450"},{"d":"Endpoint Determination","mj":true,"ui":"D023381"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Outcome Assessment, Health Care","mj":false,"qs":[{"q":"standards","mj":false,"ui":"Q000592"}],"ui":"D017063"},{"d":"Patient Selection","mj":false,"ui":"D018579"},{"d":"Prostate-Specific Antigen","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D017430"},{"d":"Prostatic Neoplasms","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"},{"q":"pathology","mj":true,"ui":"Q000473"},{"q":"therapy","mj":false,"ui":"Q000628"}],"ui":"D011471"},{"d":"Research Design","mj":false,"qs":[{"q":"standards","mj":true,"ui":"Q000592"}],"ui":"D012107"},{"d":"Testosterone","mj":false,"qs":[{"q":"blood","mj":true,"ui":"Q000097"}],"ui":"D013739"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"}],"chemicals":[{"n":"Testosterone","ui":"D013739","reg":"3XMK78S47O"},{"n":"Prostate-Specific Antigen","ui":"D017430","reg":"EC 3.4.21.77"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2007.12.4487?role=tab","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/702a10013255378ba8463bda8395026cc99cb89d","s2_open_access_license":null,"s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"PURPOSE: To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. METHODS: A committee of investigators experienced in conducting trials for prostate cancer defined new consensus criteria by reviewing previous criteria, Response Evaluation Criteria in Solid Tumors (RECIST), and emerging trial data. RESULTS: The Prostate Cancer Clinical Trials Working Group (PCWG2) recommends a two-objective paradigm: (1) controlling, relieving, or eliminating disease manifestations that are present when treatment is initiated and (2) preventing or delaying disease manifestations expected to occur. Prostate cancers progressing despite castrate levels of testosterone are considered castration resistant and not hormone refractory. Eligibility is defined using standard disease assessments to authenticate disease progression, prior treatment, distinct clinical subtypes, and predictive models. Outcomes are reported independently for prostate-specific antigen (PSA), imaging, and clinical measures, avoiding grouped categorizations such as complete or partial response. In most trials, early changes in PSA and/or pain are not acted on without other evidence of disease progression, and treatment should be continued for at least 12 weeks to ensure adequate drug exposure. Bone scans are reported as \"new lesions\" or \"no new lesions,\" changes in soft-tissue disease assessed by RECIST, and pain using validated scales. Defining eligibility for prevent/delay end points requires attention to estimated event frequency and/or random assignment to a control group. CONCLUSION: PCWG2 recommends increasing emphasis on time-to-event end points (ie, failure to progress) as decision aids in proceeding from phase II to phase III trials. Recommendations will evolve as data are generated on the utility of intermediate end points to predict clinical benefit.","claims":[{"public_id":"cl_9919eb3158a395b2d098754c87df2836","status":"active","text":"Bone scans are reported as 'new lesions' or 'no new lesions,' changes in soft-tissue disease are assessed by RECIST, and pain is measured using validated scales.","confidence":0.95,"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_9919eb3158a395b2d098754c87df2836"},{"public_id":"cl_df5b0f9c200a1ad5d4b8fb484c271e5f","status":"active","text":"Outcomes in prostate cancer trials should be reported independently for PSA, imaging, and clinical measures, avoiding grouped categorizations such as complete or partial response.","confidence":0.93,"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_df5b0f9c200a1ad5d4b8fb484c271e5f"},{"public_id":"cl_952f89ed71f2af20a33e68f78f6cc281","status":"active","text":"PCWG2 recommends a two-objective paradigm for clinical trials: controlling or eliminating existing disease manifestations and preventing or delaying expected future ones.","confidence":0.97,"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_952f89ed71f2af20a33e68f78f6cc281"},{"public_id":"cl_7e801db680a24d55725cfa0d7bfef61d","status":"active","text":"PCWG2 recommends increasing emphasis on time-to-event endpoints as decision aids when proceeding from phase II to phase III trials.","confidence":0.95,"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_7e801db680a24d55725cfa0d7bfef61d"},{"public_id":"cl_dae9da4d4455a10461ed6fb62644004a","status":"active","text":"Prostate cancers progressing despite castrate testosterone levels are classified as castration resistant, not hormone refractory.","confidence":0.95,"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_dae9da4d4455a10461ed6fb62644004a"}],"concepts":[{"public_id":"co_0d75b5d38478dc6e52c67cea69b7a430","status":"active","name":"castrate levels of testosterone","description":"Serum testosterone levels achieved through castration, used to define the patient population eligible for these trials.","types":["biological threshold","eligibility criterion"],"aliases":[],"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_0d75b5d38478dc6e52c67cea69b7a430"},{"public_id":"co_0da72348243acbcee406e0607564248c","status":"active","name":"bone scan","description":"An imaging modality used to detect bone metastases, reported as 'new lesions' or 'no new lesions' in prostate cancer trials.","types":["imaging method","outcome measure"],"aliases":[],"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_0da72348243acbcee406e0607564248c"},{"public_id":"co_43c802af528d9e98c8ff3ca689a14256","status":"active","name":"pain assessment","description":"Measurement of pain using validated scales as an independently reported clinical outcome in prostate cancer trials.","types":["outcome measure"],"aliases":[],"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_43c802af528d9e98c8ff3ca689a14256"},{"public_id":"co_4948f18c289c2266133a04ad7e2a3d6d","status":"active","name":"prostate-specific antigen","description":"A biomarker used as one independently reported outcome measure in prostate cancer clinical trials.","types":["biomarker","outcome measure"],"aliases":["PSA"],"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_4948f18c289c2266133a04ad7e2a3d6d"},{"public_id":"co_4a0d96d22e23bcde725a5488fc2facec","status":"active","name":"Prostate Cancer Clinical Trials Working Group","description":"A committee of experienced investigators that developed the PCWG2 consensus criteria for prostate cancer clinical trial design and endpoint reporting.","types":["organization"],"aliases":["PCWG2"],"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_4a0d96d22e23bcde725a5488fc2facec"},{"public_id":"co_5d52c2c274b4bb6a4971b1f4d0ee1b55","status":"active","name":"soft-tissue disease","description":"Non-bone tumor manifestations assessed by RECIST as an independently reported imaging outcome in prostate cancer trials.","types":["disease manifestation"],"aliases":[],"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_5d52c2c274b4bb6a4971b1f4d0ee1b55"},{"public_id":"co_7c14a8974078dec5cfec724b314a24ae","status":"active","name":"time-to-event endpoints","description":"Outcome measures based on the time until a specified event such as disease progression, recommended as decision aids for trial phase progression.","types":["outcome measure"],"aliases":["failure to progress"],"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_7c14a8974078dec5cfec724b314a24ae"},{"public_id":"co_91b27c0bf4975ad118e6186096de12d2","status":"active","name":"castration-resistant prostate cancer","description":"Prostate cancer that continues to progress despite castrate levels of testosterone, distinguished from the older label 'hormone refractory.'","types":["condition"],"aliases":["CRPC"],"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_91b27c0bf4975ad118e6186096de12d2"},{"public_id":"co_c1ad38bcedf954191f30c952f89e87e4","status":"active","name":"two-objective paradigm","description":"PCWG2's recommended clinical trial framework combining a controlling/relieving objective with a preventing/delaying objective.","types":["framework"],"aliases":[],"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_c1ad38bcedf954191f30c952f89e87e4"},{"public_id":"co_e4c90758f81a019754c9015da99b4432","status":"active","name":"Response Evaluation Criteria in Solid Tumors","description":"A standardized framework used to assess changes in soft-tissue disease in prostate cancer trials.","types":["evaluation criteria"],"aliases":["RECIST"],"contributors":[{"id":171,"public_id":"b9tnx83g25","public_label":"eunsjani (b9tnx83g25)","roles":["extraction"],"url":"https://sah.borca.ai/u/b9tnx83g25"},{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["review"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_e4c90758f81a019754c9015da99b4432"}],"external_ids":{"DOI":"10.1200/JCO.2007.12.4487","ArXiv":null,"PubMed":18309951,"PubMedCentral":"PMC4010133","MAG":2167331614,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2007.12.4487?role=tab","landing_url":"https://www.semanticscholar.org/paper/702a10013255378ba8463bda8395026cc99cb89d","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632178,"paper_uid":"57ce7600-e0f4-4f14-a72b-3039e3a1bb08","canonical_identity":{"paper_id":632178,"paper_uid":"57ce7600-e0f4-4f14-a72b-3039e3a1bb08","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/9449984"}